The American Society of Clinical Oncology (ASCO) applauds President Biden for his decision to appoint ASCO-Past President Monica M. Bertagnolli, MD, FACS, FASCO, as the new Director of the National Cancer Institute (NCI). An accomplished cancer surgeon and researcher with deep expertise in community-based cancer research, Dr. Bertagnolli has the knowledge, passion, and skillset to successfully lead the nation’s top federal cancer research agency and the wider U.S. cancer research enterprise. We enthusiastically endorse her selection, recognizing Dr. Bertagnolli’s distinguished leadership and experience in advancing evidence-based cancer care and research.
August 10, 2022
July 25, 2022
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials.
July 22, 2022
Alexandria, Va.
July 7, 2022
ASCO’s CancerLinQ and Owkin announced today a new research collaboration to use artificial intelligence to analyze real-world oncology data with the aim to understand why some cases of metastatic non-small cell lung cancer (NSCLC) are resistant to first-line immunotherapy treatment.
June 23, 2022
“The Association for Clinical Oncology (ASCO) applauds the Food and Drug Administration’s (FDA) decision to remove Juul products from the market in the United States (U.S.). This is an important step in preventing another generation from becoming addicted to nicotine—regardless of how it is delivered.”
June 8, 2022
One June 8, CancerLinQ® LLC and HealthVerity, Inc., today announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies.
June 7, 2022
Based on guidance from biomarker screening, patients who are 55 years of age and older with low-grade luminal A-type breast cancer may only need endocrine therapy following breast conserving surgery and could avoid radiation therapy entirely, according to new research findings that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 6, 2022
Two targeted therapies, dabrafenib (Taflinar®) plus trametinib (Mekinst®), significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation-positive low-grade gliomas. Secondary findings showed an improved clinical benefit rate and prolonged progression-free survival for dabrafenib plus trametinib compared to carboplatin plus vincristine, according to new research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2022
The use of panitumumab (Vectibix®) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared to patients who received mFOLFOX6, a standard chemotherapy regimen, plus bevacizumab (Avastin®), a monoclonal antibody, according to a finding that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2022
The use of trastuzumab deruxtecan (Enhertu®), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared to standard-of-care treatment with conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor, regardless of hormone receptor status. These practice-changing findings identify a new subset of breast cancer - called HER2-low - and redefine how a large proportion of metastatic patients will be treated. This new research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2022
Use of high-dose ifosfamide (Ifex®) was found to be superior for treating recurrent and primary refractory Ewing sarcoma compared to three other standard-of-care treatments that are used for the disease, according to research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2022
The use of autologous stem cell transplant (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed multiple myeloma patients compared to patients who received chemotherapy without an initial transplant. No overall survival benefit has yet been seen using ASCT early compared to keeping it in reserve.
June 4, 2022
In a collaboration announced on June 4, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the U.N. Sustainable Development Goals and WHO Global Action Plan on Non-Communicable Diseases and help cancer professionals provide the best possible care to their patients.
June 4, 2022
In patients with stage II colon cancer, for which cancer DNA was not present in the blood (circulating tumor DNA, or ctDNA) post-surgical chemotherapy could be skipped without compromising recurrence-free survival. Conversely, for patients where ctDNA was present after surgery, the rate of recurrence among those who received chemotherapy was low, suggesting a survival benefit from post-surgical chemotherapy, according to new research to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2022
The use of sacituzumab govitecan (Trodelvy®) an antibody-drug conjugate, resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many prior therapies and who had hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, according to new research to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pages |